Forian (NASDAQ:FORA) Receives “Buy” Rating from Roth Mkm

Roth Mkm reiterated their buy rating on shares of Forian (NASDAQ:FORA) in a research report released on Thursday morning,Benzinga reports. They currently have a $5.00 price objective on the stock.

Forian Stock Performance

Shares of NASDAQ FORA traded down $0.03 during trading on Thursday, hitting $2.00. 12,236 shares of the company traded hands, compared to its average volume of 15,829. Forian has a fifty-two week low of $1.99 and a fifty-two week high of $4.15. The firm has a market capitalization of $62.22 million, a price-to-earnings ratio of 40.60 and a beta of 1.09. The business’s fifty day moving average is $2.14 and its 200 day moving average is $2.44.

Forian (NASDAQ:FORA) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.06). The firm had revenue of $4.78 million for the quarter, compared to analysts’ expectations of $5.26 million. During the same quarter in the prior year, the business posted ($0.03) EPS.

Institutional Investors Weigh In On Forian

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FORA. Canton Hathaway LLC lifted its position in Forian by 2.3% during the third quarter. Canton Hathaway LLC now owns 269,650 shares of the company’s stock worth $582,000 after buying an additional 6,125 shares in the last quarter. Caprock Group LLC acquired a new position in Forian during the 2nd quarter worth approximately $230,000. Finally, Elser Financial Planning Inc acquired a new stake in Forian during the 2nd quarter valued at $1,885,000. 19.25% of the stock is currently owned by hedge funds and other institutional investors.

Forian Company Profile

Forian Inc provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the healthcare and related industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions.